Variable | Model 1 | Model 2 | Model 3 | ||||||
---|---|---|---|---|---|---|---|---|---|
β | 95%CI | p value | β | 95%CI | p value | β | 95%CI | p value | |
Total score | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Mirabegron started in 4th year | − 5.86 | − 9.15, − 2.57 | 0.001 | − 5.79 | − 9.10, − 2.49 | 0.001 | − 5.82 | − 9.13, − 2.50 | 0.001 |
HAM-BDSS (3rd year) | 0.88 | 0.80, 0.96 | < 0.001 | 0.87 | 0.79, 0.95 | < 0.001 | 0.86 | 0.78, 0.95 | < 0.001 |
Age (1-year increase) | – | – | – | − 0.02 | − 0.09, 0.05 | 0.592 | − 0.02 | − 0.08, 0.05 | 0.673 |
Sex (female vs. male) | – | – | – | − 0.93 | − 2.61, 0.77 | 0.281 | − 0.79 | − 2.54, 0.96 | 0.373 |
α1 adrenergic-receptor antagonists | – | – | – | – | – | – | 1.80 | − 0.45, 4.03 | 0.115 |
Cholinergic agonists | – | – | – | – | – | – | − 1.75 | − 5.44, 1.94 | 0.350 |
Anticholinergics | – | – | – | – | – | – | 0.37 | − 1.97, 2.71 | 0.752 |
Storage symptom score | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Mirabegron started in 4th year | − 2.73 | − 5.06, − 0.41 | 0.022 | − 2.64 | − 4.97, − 0.32 | 0.026 | − 2.72 | − 5.02, − 0.42 | 0.021 |
HAM-BDSS (3rd year) | 0.81 | 0.69, 0.92 | < 0.001 | 0.79 | 0.67, 0.90 | < 0.001 | 0.79 | 0.68, 0.91 | < 0.001 |
Age (1-year increase) | – | – | – | –0.002 | − 0.05, 0.05 | 0.926 | 0.00 | − 0.05, 0.05 | 0.994 |
Sex (female vs. male) | – | – | – | − 0.94 | − 2.11, 0.23 | 0.115 | − 1.04 | − 2.24, 0.16 | 0.088 |
α1 adrenergic-receptor antagonists | – | – | – | – | – | – | 0.85 | − 0.68, 2.38 | 0.275 |
Cholinergic agonists | – | – | – | – | – | – | − 1.45 | − 4.00, 1.09 | 0.261 |
Anticholinergics | – | – | – | – | – | – | 1.44 | − 0.17, 3.05 | 0.079 |
Voiding symptom score | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Mirabegron started in 4th year | − 2.83 | − 4.81, − 0.87 | 0.005 | − 2.83 | − 4.82, − 0.84 | 0.006 | − 2.81 | − 4.80, − 0.82 | 0.006 |
HAM-BDSS (3rd year) | 0.92 | 0.85, 0.99 | < 0.001 | 0.92 | 0.84, 0.99 | < 0.001 | 0.91 | 0.83, 0.99 | < 0.001 |
Age (1-year increase) | – | – | – | − 0.01 | − 0.05, 0.03 | 0.626 | − 0.01 | − 0.05, 0.03 | 0.662 |
Sex (female vs male) | – | – | – | − 0.02 | − 1.04, 0.99 | 0.963 | 0.22 | − 0.83, 1.26 | 0.679 |
α1 adrenergic-receptor antagonists | – | – | – | – | – | −  | 0.82 | − 0.53, 2.17 | 0.232 |
Cholinergic agonists | – | – | – | – | – | – | − 0.15 | − 2.37, 2.07 | 0.893 |
Anticholinergics | – | – | – | – | – | – | − 1.06 | − 2.46, 0.35 | 0.139 |